CDK12 and acute myeloid leukemia: In contrast, the sensitivity of healthy cells and AML cells to the CDK12 degrader BSJ-4-11651 was comparably low (Supplementary Fig. 7A), which is likely attributed to the very high potency of BSJ-4-116 that precluded the faithful evaluation of a potential therapeutic window.